c-MYC is a well-validated oncogene with broad anti-cancer potential, as c-MYC expression is dysregulated in more than 70% of cancers and a key regulator in nearly every aspect of the oncogenic ...

Obesity elevates the risk of at least 13 major cancers, including those of the breast, colon and liver. It also impairs immune responses that target tumors and are stimulated by cancer immunotherapies ...

Scientists have developed a chemical method to reverse aging in human cells without the need for genetic modification.

A. 3HA-c-Myc was co-expressed with FLAG-USP17 (WT or the catalytically inactive mutant (C89S)) in COS7 cells. After 24 h, cell lysates were immunoblotted with the indicated antibodies.

They found that overexpression of c-Myc in Atp4b+ gastric parietal cells could induce gastric adenoma in mice. Mechanistically, c-Myc promoted tumorigenesis via the AKT/mTOR pathway.

Targeting MYC is therefore highly desirable. Still, finding c-MYC inhibitors for therapeutic use has been problematic and MYC itself has long been viewed as "undruggable".

Besides, c-Myc is also known as a factor necessary for the initial induction of iPS cells. In the future this inhibition can be expected to be applied as a technology that can also be used to ...

c-Myc plays a regular part in this protein production process—and cellular growth in general—and humans could not live without it. Occasionally, this process is disrupted.

Conclusions: A high c-Myc expression in naïve CC might discriminate patients with a lower TTP and a worse prognosis. Moreover, the significant c-Myc pathway upregulation, unrelated to miRNAs ...

c-myc nullizygous fibroblasts (KO cells) were used to compare the abilities of c-myc, N-myc and L-myc oncoproteins to accelerate growth, promote apoptosis, revert morphology, and regulate the ...